Abstract
Characterized by childhood onset of motor and phonic tics, Tourette syndrome is a neurodevelopmental disorder often accompanied by behavioral and psychiatric comorbidities. In the ARTISTS2 (Alternatives for Reducing Tics in Tourette Syndrome 2) study, deutetrabenazine, a vascular monoamine transport 2 inhibitor approved for the treatment of chorea associated with Huntington disease and tardive dyskinesia, was studied for the treatment of Tourette syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
